This drug firm gets nod for clinical trials of Covid-19 therapy
Drug firm Zydus Cadila on Friday said it has received approval from Mexico's regulatory authority Cofepris to conduct clinical trials
Covid-19 vaccine
New Delhi: Drug firm Zydus Cadila on Friday said it has received approval from Mexico's regulatory authority Cofepris to conduct clinical trials in the Latin American country with its biological therapy "Pegylated Interferon alpha-2b" for treatment of Covid-19.
Zydus Cadila said it had received approval from the Mexican regulatory authority Cofepris to conduct clinical trials with its biological therapy, Pegylated Interferon alpha-2b, 'PegiHepTM'.
It added that this will be an open-label, randomised, comparator controlled study to evaluate safety, efficacy and tolerability in patients with Covid-19.